Acyclovir in cancer patients?

Acyclovir is commonly used in cancer patients to prevent or treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections during chemotherapy or after stem cell transplant when the immune system is suppressed. It’s generally well tolerated but requires attention to kidney function and hydration.

Key points

- Why it’s used in cancer patients
- Prophylaxis to prevent HSV/VZV reactivation during periods of immunosuppression.
- Treatment of active HSV or VZV infections (including shingles) in immunocompromised patients, where disease can be more severe or disseminated.
- Not effective against CMV; CMV prophylaxis or treatment uses other drugs (e.g., ganciclovir/valganciclovir).

- How it’s given
- Oral and IV forms are available.
- Dosing depends on the infection (HSV vs VZV vs disseminated disease), severity, and kidney function.
- Typical patterns (for reference only; exact dosing must be prescribed by a clinician):
- Treatment of HSV/VZV infections (adult): higher-dose regimens orally or IV for severe cases. IV regimens are usually 10 mg/kg every 8 hours for severe disease (often 7–10 days), then switch to oral to complete the course as symptoms improve.
- Shingles (VZV): often 800 mg orally five times daily for 7–10 days.
- Oral treatment for less severe HSV: regimens like 400 mg orally five times daily for 5–10 days are used in many situations.
- Prophylaxis/suppressive therapy during ongoing immunosuppression: commonly around 400 mg orally twice daily (some regimens use 400 mg three times daily); exact choice depends on risk and clinician preference.
- In hospitalized high-risk patients, short courses of IV acyclovir (often 5 mg/kg IV every 8 hours) may be used.

- Safety and monitoring
- Main risk is kidney-related (nephrotoxicity from crystallization). Ensure good hydration, monitor kidney function, and adjust dose for reduced renal function.
Increased risk when used with other nephrotoxic drugs (e.g., certain chemotherapy agents, aminoglycosides).
IV administration can cause phlebitis; irritation at the IV site.
Rarely, neurotoxicity (confusion, tremor, seizures) with very high doses or in kidney impairment.
Acyclovir does not treat CMV infections; CMV require different antiviral therapy.

- Resistance
- Acyclovir resistance can occur in severely immunocompromised patients (often due to thymidine kinase mutations). If there is poor response, doctors may switch to alternatives such as foscarnet or cidofovir.

If you want, tell me:
- Are you asking about prophylaxis during chemotherapy or stem cell transplant, or treatment of a current HSV/VZV infection?
- What cancer type and what is the patient’s kidney function (creatinine clearance)?
- Any other meds or concerns (e.g., CMV risk, IV vs oral route)?

I can tailor dosing ranges and considerations to a specific situation. And as always, please consult the treating oncologist or infectious disease specialist for dosing and monitoring in a real patient.